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Abstract
Alzheimer’s disease (AD) is characterized by the intracranial accumulation of the 4 kDa amyloid-L peptide (AL), following
proteolysis of a V700-amino acid, integral membrane precursor, the Alzheimer amyloid precursor protein (APP). The best
evidence causally linking APP to AD has been provided by the discovery of mutations within the APP coding sequence that
segregate with disease phenotypes in autosomal dominant forms of familial AD (FAD). Though FAD is rare (6 10% of all
AD), the hallmark features (amyloid plaques, neurofibrillary tangles, synaptic and neuronal loss, neurotransmitter deficits
and dementia) are indistinguishable when FAD is compared with typical, common, ‘non-familial’, or sporadic, AD (SAD).
Studies of some clinically relevant mutant APP molecules from FAD families have yielded evidence that APP mutations can
lead to the enhanced generation or aggregability of AL, consistent with a pathogenic role in AD. Other genetic loci for FAD
have been discovered which are distinct from the immediate regulatory and coding regions of the APP gene, indicating that
defects in molecules other than APP can also specify cerebral amyloidogenesis and FAD. To date, all APP and non-APP
FAD mutations can be demonstrated to have the common feature of promoting amyloidogenesis of AL. Epidemiological
studies indicate that postmenopausal women on estrogen replacement therapy (ERT) have their relative risk of developing
SAD diminished by about one third as compared with age-matched women not receiving ERT [M.X. Tang, D. Jacobs, Y.
Stern, K. Marder, P. Schofield, B. Gurland, H. Andrews, R. Mayeux, Effect of estrogen during menopause on risk and age at
onset of Alzheimer’s disease, Lancet 348 (2000) 429^432]. Because of the key role of cerebral AL accumulation in initiating
AD pathology, it is most attractive that estradiol might modulate SAD risk or age-at-onset by inhibiting AL accumulation. A
possible mechanistic basis for such a scenario is reviewed here. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Alzheimer’s disease (AD) is associated with
intracranial amyloidosis
Amyloid is a generic description applied to a het-
erogeneous class of tissue protein precipitates which
have the common feature of a L-pleated sheet sec-
ondary structure, a characteristic which confers a⁄n-
ity for the histochemical dye Congo red. Amyloids
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may be deposited in a general manner throughout
the body (systemic amyloids) or con¢ned to a partic-
ular organ (e.g. cerebral amyloid, renal amyloid).
AD is characterized by clinical evidence of cognitive
failure in association with cerebral amyloidosis, cer-
ebral intraneuronal neuro¢brillary pathology, neuro-
nal and synaptic loss and neurotransmitter de¢cits.
The cerebral amyloid of AD is deposited around
meningeal and cerebral vessels, as well as in gray
matter. In gray matter, the deposits are multifocal,
coalescing into miliary structures known as plaques.
Parenchymal amyloid plaques are distributed in
brain in a characteristic fashion, di¡erentially a¡ect-
ing the various cerebral and cerebellar lobes and
cortical laminae.
The main constituent of cerebrovascular amyloid
was puri¢ed and sequenced by Glenner and Wong in
1984. This 40^42 amino acid polypeptide, designated
‘L protein’ (or, according to Masters et al., ‘A4’; now
standardized as ‘AL’ by The Husby Commission), is
derived from a 695^770 amino acid precursor,
termed the amyloid precursor protein (APP; Fig.
1), which was characterized by molecular cloning us-
ing oligonucleotide probes from the published amy-
loid peptide sequence. The primary citations for this
molecular neuropathology review can be found else-
where [1].
2. AL is a catabolite of an integral precursor
The deduced amino acid sequence of APP predicts
a protein with a single transmembrane domain (Fig.
1A). Isoform diversity is generated by alternative
mRNA splicing and isoforms of 751 and 770 amino
acids include a protease inhibitor domain (‘Kunitz-
type protease inhibitor’ domain, or KPI) in the ex-
tracellular region of the APP molecule. The ectodo-
mains of the protease inhibitor-bearing isoforms of
APP are identical to molecules previously identi¢ed
according to their tight association with proteases
and thus were designated ‘protease nexin II’ (‘PN-
II’). Identical molecules are also present in the plate-
let K-granules, where they were described under the
name of ‘factor XIa inhibitor’ (XIaI). Upon degranu-
lation of the platelet, factor XIaI (PN-II/APP) exerts
an antiproteolytic e¡ect on activated factor XIa at
late steps of the coagulation cascade. Some evidence
suggests that KPI-lacking isoforms may also act as
regulators of proteolysis. While many bioactivities
for APP have been catalogued in the literature, AL
might simply be a by-product of APP metabolism
which is not necessarily intimately involved with
APP function.
The proteolytic processing steps for APP have by
now been de¢nitively identi¢ed by puri¢cation and
sequencing. The ¢rst to be identi¢ed involves cleav-
age within the AL domain. A large amino-terminal
fragment of the APP extracellular domain (PN-II; or
s-APPK or APPsK, for soluble APPK is released into
the medium of cultured cells and into the cerebrospi-
nal £uid, leaving a small nonamyloidogenic carboxy-
terminal fragment associated with the cell. This path-
way is designated the K-secretory cleavage/release
processing pathway for APP, because the enzyme(s)
which perform(s) this nonamyloidogenic cleavage/re-
lease has been designated K-secretase. Thus, one im-
portant processing event in the biology of APP acts
to preclude amyloidogenesis by proteolyzing APP
within the AL domain, between residues AL16 and
AL17 (Fig. 1B).
Until mid-1992, the prevailing notion was that AL
production might be restricted to the brain and per-
haps even then only in association with aging and
AD. This concept became obsolete with the discov-
ery by several groups that a soluble AL species (pre-
sumably a forerunner of the aggregated ¢brillar spe-
cies which is deposited in senile plaque cores) is
detectable in body £uids from various species and
in the conditioned medium of cultured cells. Still,
AL, ‘soluble AL’ (to distinguish it from deposited
AL amyloid) is not readily detectable in the lysates
of most cultured cells. Soluble AL is apparently gen-
erated in several cellular compartments, including the
endoplasmic reticulum, the Golgi apparatus, the
trans-Golgi network and endosomes. AL production
might begin by cleavage at the AL amino-terminus
by another enzyme designated L-secretase (Fig. 1B),
probably beginning in the constitutive secretory
pathway, i.e. the trans-Golgi network (TGN). This
model accounts especially well for providing a codis-
tribution opportunity involving APP and L-secretase
prior to APP’s encounter with the AL-domain-de-
stroying K-secretase which appears to act primarily
at the plasma membrane. Data from one FAD mu-
tant (the ‘Swedish’ FAD mutant; Fig. 1B; discussed
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in detail below) support this model strongly. Other
data indicate that at least some AL arises from APP
molecules following their residence at the cell sur-
face; presumably these APP molecules have escaped
cell-surface K-secretase and have been internalized
intact, encountering L-secretase in an endosome.
An AL variant bearing Glu11 at its N-terminus has
been recently noted as a prominent product of APP
metabolism in cultured neurons [2]. The generation
and pharmacologic regulation of [Glu11] AL forma-
tion appears to parallel that observed for standard
[Asp1] AL1ÿx. The cellular and biochemical origin of
the alternative cleavage at Glu11 and its role in amy-
loidogenesis, if any, are all yet to be elucidated.
It is important to appreciate that one area of par-
ticular current interest is the elucidation of the mo-
lecular and cellular mechanisms by which the car-
boxy-terminus of AL is generated, since this region
of the APP molecule resides within an intramembra-
nous domain (Fig. 1). The protease(s) responsible for
that cleavage, designated the Q secretase(s) (Fig. 1B),
are particularly interesting not only because of the
novelty of the active site-substrate reaction (i.e. with-
in a membranous domain) but also owing to evi-
dence that another class of FAD (known as preseni-
lin-related FAD; [3]) appears to act via control of
Q secretase function [4,5]. Along this line, the AL
C-terminus is heterogeneous, being composed mostly
of peptides terminating at residue AL40 (Fig. 1B);
however, a small but important minority of peptides
terminate at residue AL42 (Fig. 1), and it is these
highly aggregatable peptides which are believed to
Fig. 1. Structure of the Alzheimer APP (A), including the ¢ne structure around the AL domain (B). The long intralumenal (or, under
certain circumstances, extracellular) domain is directed leftward whilst the short cytoplasmic domain is directed rightward. FAD = fa-
milial AD.
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initiate AL accumulation in all forms of the disease
[6,7].
The primary citations for the foregoing review of
APP processing can also be found elsewhere [1].
3. Pathogenic APP mutations occur within or near the
AL domain, yield APP molecules which display
pro-amyloidogenic properties in vitro and
Alzheimer-like phenotypes in transgenic mouse
models in vivo
Certain mutations associated with familial cerebral
amyloidoses have been identi¢ed within or near the
AL region of the coding sequence of the APP gene.
These mutations segregate with the clinical pheno-
types of either hereditary cerebral hemorrhage with
amyloidosis, Dutch type (HCHWAD, or FAD-
Dutch; Fig. 1B) or more typical familial AD (‘Brit-
ish’, ‘Indiana’ FAD; Fig. 1B) and provide support
for the notion that aberrant APP metabolism is a key
feature of AD.
In FAD-Dutch, an uncharged glutamine residue is
substituted for a charged glutamate residue at posi-
tion 22 of AL (Fig. 1B). This mutated residue is
located in the extracellular region of APP, within
the AL domain, where it apparently exerts its pro-
amyloidogenic e¡ect by generating AL molecules
which bear enhanced aggregation properties and per-
haps also by altering K secretase cleavage. A ‘Flem-
ish’ form of FAD involves a mutation at position 21
of AL (Fig. 1B) and generates a phenotype inter-
mediate between the relatively pure vascular amy-
loidosis of ‘Dutch FAD’ and the more typical FAD
involving parenchymal and vascular amyloidosis.
Mutations in APP which are apparently pathogen-
ic for more typical FAD have also been discovered.
In the ¢rst discovered FAD mutation, an isoleucine
residue is substituted for a valine residue within the
transmembrane domain, at a position two residues
downstream from the carboxy-terminus of the AL
domain (Fig. 1B), equivalent to ‘AL44’ (if such a
position existed). Although a conservative substitu-
tion, the mutation segregates with FAD in pedigrees
of American, European (‘British’) and Asian origins,
arguing against the possibility that the mutations
represent irrelevant polymorphisms. Other pedigrees
have been discovered in which a¡ected members
have either phenylalanyl (‘Indiana’) or glycyl residues
at position ‘AL44’. Neuropathological examination
has veri¢ed the similarity of these individuals to typ-
ical SAD neuropathology. These ‘AL44’ mutant
APPs are the most common of the FAD-causing
APP mutations and the mechanism by which the
mutations exert their e¡ects appears to be by enhanc-
ing generation of hyperaggregable, C-terminally ex-
tended AL peptides (especially AL42).
Another FAD pedigree has been established in-
volving a large Swedish kindred. In this instance,
tandem missense mutations occur just upstream of
the amino-terminus of the AL domain. Transfection
of cultured cells with APP molecules containing the
‘Swedish’ missense mutations results in the produc-
tion of six- to eight-fold excess soluble AL above that
generated from wild-type APP. An important issue
for clari¢cation in sporadic AD will be to establish
whether hyperaggregation or hyperproduction of AL
(or neither) is/are important predisposing factor(s) to
this much more commonly encountered clinical en-
tity. The primary citations for the foregoing review
of the genetic-neuropathological correlations of APP
mutant FAD can be found elsewhere [1].
Some of the most exciting and newest evidence in
support of the pathogenicity of these mutants has
arisen from the recent demonstration that certain
mutant APP transgenic mice exhibit not only cere-
bral amyloidosis but also neuro¢brillary tangle epi-
topes and neuronal loss [8]. If these animals also
meet key behavioral criteria, Koch’s postulates will
have been met for the re-creation of all key features
of AD in a species not otherwise susceptible to the
illness.
4. Signal transduction regulates the relative utilization
of APP processing pathways in cultured cell lines,
in primary neurons and in rodents in vivo
As work continues toward molecular discovery of
K-, L- and Q- secretase enzymes, substantial progress
has been made toward understanding the regulation
of APP cleavage. For example, the relative utilization
of the various alternative APP processing pathways
appears to be at least partially cell-type determined,
with transfected AtT20 cells secreting virtually all
APP molecules whereas cell lines of astrocytic origin
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release little or no soluble APP. In neuronal-like
cells, the state of di¡erentiation plays a role in deter-
mining the relative utilization of the pathways, with
the di¡erentiated neuronal phenotype being associ-
ated with relatively diminished basal utilization of
the nonamyloidogenic K-secretase cleavage/release
pathway.
It is also well-accepted that certain signal trans-
duction systems involving protein phosphorylation
are important regulators of APP cleavage, acting in
many cases by stimulating the relative activity of
nonamyloidogenic cleavage by K-secretase. The role
of protein kinase C (PKC) and PKC-linked ¢rst mes-
sengers has received the most attention. In many
types of cultured cells, activation of PKC by phorbol
esters dramatically stimulates APP proteolysis [9]
and sAPPK cleavage/release [10^12]. PKC-stimulated
K-secretory cleavage of APP may also be induced by
the application of neurotransmitters and other ¢rst
messenger compounds whose receptors are linked to
PKC [13,14]. Okadaic acid, an inhibitor of protein
phosphatases 1 and 2A, also increases APP proteol-
ysis and release via the K-secretase pathway [13,14].
Indeed, it has recently been shown in primary neuro-
nal cultures that protein phosphatase inhibition by
okadaic acid is much more e¡ective in lowering AL
production than is PKC activation [2]. Thus, either
stimulation of PKC or inhibition of protein phospha-
tases 1 and 2A is su⁄cient to produce a dramatic
acceleration of nonamyloidogenic APP degradation
(not shown). PKC-activated APP processing can be
demonstrated to diminish the generation of AL in
virtually every situation tested to date, including pri-
mary neuronal cultures and rodent brain in vivo [15^
17]. This phenomenon is sometimes referred to as
‘regulated cleavage of APP’ or ‘reciprocal regulation
of APP metabolism’; i.e. when certain signals are
activated, K secretase cleavage increases and L and
Glu11-secretase cleavages decrease [2].
Steroid hormones such as 17L-estradiol [18^20]
and dihydroepiandrostenedione (DHEA; [21]) are
other signal transduction compounds which can ap-
parently regulate APP metabolism in vitro. Several
of these investigators [19,20] have demonstrated that
estradiol diminishes AL generation, while others
[18,21] have documented accumulation of sAPPK in
the conditioned media of cultured cells treated with
estradiol [18] or DHEA [21]. One attractive explan-
ation for the accumulation of sAPP is that gonadal
steroids might stimulate either the amount or the
activity of K-secretase. This explanation is consistent
with the ¢nding that the cell-associated product of
this activity (the 9-kDa nonamyloidogenic carboxy-
terminal fragment) is increased by estrogen treatment
[18]. For estradiol in particular, one means by which
the activity of K-secretase might increase is by an
increase in the level or activity of PKC, leading to
increased ‘regulated APP cleavage’ along the path-
way outlined above. Estrogen has been shown to
regulate PKC in both normal and neoplastic tissue
and to potentiate the phorbol ester-stimulated release
of luteinizing hormone from cultured pituitary cells.
The e¡ects of estrogen on PKC might be mediated
by polypeptide growth factors, many of which acti-
vate PKC and a number of which have been demon-
strated to enhance the accumulation of sAPPK in the
conditioned media of cultured cells. The colocaliza-
tion of estrogen receptors in the basal forebrain, cer-
ebral cortex and hippocampus with the receptors for
nerve growth factor, as well as with nerve growth
factor itself, is consistent with the idea that growth
factors might play a role in mediating the e¡ects of
estrogen in the central nervous system. A review of
the literature associating estradiol with protein ki-
nase may be found elsewhere [18].
Extending this line of reasoning, a more complex
relationship involving intercellular signals and APP
metabolism is currently evolving: both steroid hor-
mones and neurotrophins have been demonstrated to
potentiate the ability of incoming neurotransmitters
to activate the ‘regulated cleavage of APP’, as meas-
ured by sAPPK release [22^26]. The ‘regulated cleav-
age’ model makes it likely that when compounds
from either or both of these classes of substances
(i.e. gonadal steroids, neurotrophins) are present at
the time of neurotransmitter application, the fold-di-
minution of AL and [Glu11] AL will be greatly en-
hanced. Assessment of this model is currently under-
way.
5. Insights into mechanism(s) of regulated APP
processing
In general terms, the possible mechanisms for ac-
tivated processing of integral molecules can be con-
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ceptualized as involving either activation or redistrib-
ution of either the substrate (i.e. APP) or the enzyme
(i.e. K-secretase). Based on APP cytoplasmic tail mu-
tational analyses [27,28], the ‘substrate activation’
model [29] is inadequate to explain activated process-
ing of APP, since abrogation of APP cytoplasmic tail
phosphorylation fails to abolish PKC-regulated K-
cleavage. In order to test the model of PKC-regu-
lated APP redistribution, Xu et al. demonstrated
that the PKC-stimulated biogenesis of nascent trans-
port vesicles from the trans-Golgi network includes
vesicles which bear [35SO4]APP [30]. These vesicles
would be predicted to fuse with the plasma mem-
brane where codistribution of APP and K-secretase
would take place, leading to generation of sAPPK at
the plasma membrane and release of that sAPPK into
the culture medium. Given the preponderant local-
ization of APP within the TGN [31], it is likely that
PKC-regulated TGN vesicle biogenesis plays a role
in regulating APP metabolism, although its impor-
tance cannot be completely assessed until the identi-
¢cation of all relevant PKC targets of this apparatus
has been completed.
Along a related line of investigation, Bosenberg et
al. [32] succeeded in demonstrating faithful activated
processing of the TGF-K precursor in porated cells in
the virtual absence of cytosol and in the presence of
N-ethylmaleimide or 2.5 M NaCl. The preservation
of activated processing under such conditions sug-
gests that extensive vesicular tra⁄cking is unlikely
to be required for all forms of activated processing
and supports a model of direct or indirect enzyme
activation which involves an intrinsic plasma mem-
brane mechanism (e.g. direct phosphorylation of an
K-secretase or its regulatory subunit). Cell biological
and molecular cloning data indicate that APP K-sec-
retases include, or are related to, the metalloprotei-
nase family of adamlysins, including TGFK and pro-
tumor necrosis factor convertases. These enzymes
appear to have overlapping speci¢cities for these sub-
strates. Several candidate secretases have recently
been successfully cloned and these data should facil-
itate the resolution of the issue of which enzymes are
most important for cleaving which substrates. [33^
36] Aspartyl proteinases are the most important K-
secretases in yeast [36], and their potential roles, if
any, in mammalian APP metabolism, remain to be
elucidated.
6. Therapeutic manipulation of AL generation via
ligand or hormonal manipulation
From a therapeutic standpoint, then, the modula-
tion of APP metabolism via signal transduction
pharmacology might be bene¢cial in individuals
with, or at risk for, AD (reviewed in [1,12,17,37])
and it is along this line that 17L-estradiol, via its
possible ability to elevate PKC activity (reviewed in
[18]), came to be identi¢ed as a potential modulator
of AL metabolism. This phenomenon is now under
investigation in living animals. The ability of estro-
gen to modulate AL metabolism in vivo was recently
tested in two animal systems: guinea pigs and plaque
forming mice (Du¡ and Refolo, personal communi-
cation; Petanceska, Nagy, Frail and Gandy, submit-
ted for publication). Prolonged ovariectomy of guin-
ea pigs was associated with a pronounced increase in
brain AL levels as compared to intact animals. This
ovariectomy-induced increase was signi¢cantly re-
duced in guinea pigs receiving 17L-estradiol. Simi-
larly, ovariectomy of transgenic, plaque forming
mice at an age when AL deposition is incipient re-
sulted in enhanced brain amyloidosis. The contribu-
tions of altered AL generation and altered AL clear-
ance to the observed changes in brain AL levels
remain to be determined. Further studies are also
needed to elucidate whether the observed e¡ects on
AL metabolism occur in response to activation of
brain estrogen receptors or whether they are medi-
ated by estrogen receptor-independent mechanisms.
However, these two studies strongly infer that cessa-
tion of ovarian estrogen production in post-meno-
pausal women might facilitate AL deposition by in-
creasing the local concentrations of AL peptides in
brain and that the negative correlation between hor-
mone replacement therapy of post-menopausal wom-
en and AD is at least in part due to the AL-lowering
e¡ect of estrogen.
Estradiol might also modify other factors contri-
buting to AL deposition and ¢bril formation, includ-
ing the processing of soluble AL into an aggregated
form and/or the association of AL with other mole-
cules, such as K-1-antichymotrypsin, heparan sulfate
proteoglycan and apolipoprotein E [38]. In particu-
lar, it has recently been recognized that apolipopro-
tein E is an important participant in AL accumula-
tion [39] and that apolipoprotein E isoforms play
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important roles as di¡erential determinants of risk
for AD [40]. Human postmortem [41] and cell culture
[42] data are also beginning to indicate that apolipo-
protein E isoforms exert at least some of their e¡ects
via controlling AL accumulation, perhaps at the
stage of clearance of AL peptides. Apolipoprotein
E-isoform-speci¢c synaptic remodelling also appears
to be a consistent and potentially relevant observa-
tion [43].
Events beyond AL deposition may also be crucial
in determining the eventual toxicity of AL plaques.
Aggregation of AL is important for in vitro models
of neurotoxicity, but the relevance of this phenom-
enon for the pathogenesis of AD is unclear, since AL
deposits may occur in normal aging, in the absence
of any evident proximate neuronal injury [44]. This
suggests that other events must distinguish ‘di¡use’
cerebral amyloidosis with wispy deposits of AL alone
from ‘full-blown’ AD with neuritic plaques, and neu-
ron and synapse loss. One intriguing possible contri-
buting factor is the association of complement com-
ponents with AL. In cerebellum, where AL deposits
appear to cause no injury, plaques are apparently
free of associated complement, while in the fore-
brain, complement associates with plaques, perhaps
becoming activated and injuring the surrounding
cells [45]. Other, as-yet undiscovered plaque-associ-
ated molecules may also play important roles.
It should also be possible to apply animal models
of AL deposition and neurodegeneration [8] to begin
to elucidate whether the e¡ect of estrogen to delay or
prevent AD in postmenopausal women is due to one
or a combination of its various documented activities
relevant to the pathogenesis of AD, i.e. lowering AL
load, sustaining the basal forebrain cholinergic sys-
tem [46], modulating interactions with growth factors
and/or their receptors [47], supporting neuritic plas-
ticity [48] or serving as an antioxidant [49]. One can-
not yet exclude the possibility that estradiol plays
several of these roles in its apparent2 ability to delay
and/or prevent AD [50,51].
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